Lundbeck Boosts US R&D Capability With $400m Abide Theraputics Bid

 
• By Mike Ward

Danish neuroscience company plans to acquire Abide Therapeutics for $250m upfront and up to $150m in milestones to access serine hydrolase drug discovery platform.

nerve cells, concept for neurodegenerative and neurological disease
Lundbeck seeks new pathways to brain diseases • Source: Shutterstock

More from Deals

More from Business